Kin-Ming Lo

Medicine · Health Sciences

29h-index4.5kcitations91works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(29), Monoclonal and Polyclonal Antibodies Research(23), Crystallization and Solubility Studies(18), X-ray Diffraction in Crystallography(18), Cancer Research and Treatments(14)

Publications90 total

Data from A Low-Toxicity IL-2–Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
2023Open Access
Figure S4 from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
2023Open Access
Figure S3 from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
2023Open Access
Figure S1 from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
2023Open Access
Figure S2 from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
2023Open Access
Figure S7 from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
2023Open Access
Figure S7 from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
2023Open Access
Figure S6 from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
2023Open Access
Supplementary Figure 1 from A Low-Toxicity IL-2–Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
2023Open Access
Figure S1 from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
2023Open Access
Data from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
2023Open Access
Figure S5 from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
2023Open Access
Figure S2 from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
2023Open Access
Figure S5 from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
2023Open Access
Supplementary Materials and Methods from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
2023Open Access
Supplementary Figure 1 from A Low-Toxicity IL-2–Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
2023Open Access
Data from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
2023Open Access
Figure S6 from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
2023Open Access
Supplementary Materials and Methods from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
2023Open Access
Figure S4 from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Stephen D. Gillies(21), Yan Lan(16), Guozhong Qin(11), Bo Marelli(10), Lan Yan(9), Kashi Javaherian(8), Beatrice Brunkhorst(8), Jin Qi(7), Huakui Yu(7), Judah Folkman(6), Chunxiao Xu(6), Molly H. Jenkins(5), Scott Lauder(5), Laszlo Radvanyi(4), Aroop Sircar(3), Vivian M. Hernández(3), George Locke(3), Tsz-Lun Yeung(3), Yaping Sun(3), Ralph A. Reisfeld(3)